pharma news today glp-1 obesity drugs Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine Race for approval of first

These inhibitors differ structurally in terms of pharmacokinetics, thus ongoing trials are crucial as no class effect can be assumed

Sleep apnea improvement: ZepBound is now FDA-approved for sleep apnea in people with obesity, as weight loss can ease symptoms like snoring and disrupted breathing

To view or add a comment, sign in GLP-1 Drugs: My Take as a Pharmacist Every week, I see articles warning about the dangers of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro

It occurs because the medication slows stomach emptying and gut motility

doi: 10.1016/j.bbr.2015.07.024

Discussion Despite recent advancements in cardiovascular prevention and treatment, cardiovascular disease remains the leading cause of death worldwide, particularly among high-risk populations such as those with type 2 diabetes and/or hypertension [1]